<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04158596</url>
  </required_header>
  <id_info>
    <org_study_id>SDX-3101</org_study_id>
    <nct_id>NCT04158596</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of SDX-3101 for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)</brief_title>
  <acronym>SDX-3101</acronym>
  <official_title>Randomised, Double-blind, Multi-centre, Clinical Trial to Assess the Safety and Efficacy of SDX-3101, an Innovative Vibration Therapy Portable Device for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) in Adult Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SynDermix AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ISS AG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SynDermix AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical trial is to assess the safety and efficacy of SDX-3101 for
      treatment of adult patients with chronic rhinosinusitis without nasal polyps (CRSsNP) by
      investigating a vibration pattern of SDX-3101 compared to a control
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic rhinosinusitis (CRS) is a common disease (e.g. 11% of adults in the UK report
      symptoms of CRS) leading to substantial health and socioeconomic burden with estimated
      healthcare costs in the USA of $772/patient/year (2011).

      CRS is characterised by the long-term presence of multiple symptoms including facial
      pain/pressure in about 80% of CRS patients. Factors contributing to the pathophysiology of
      adult CRS include allergies, bacterial biofilms, asthma and exposure to various environmental
      pollutants. Computed tomography (CT) scans are often used to identify mucosal thickening and
      to identify any comorbid factors such as anatomic abnormalities.

      It is known from the literature that low vibration frequency can improve blood flow,
      significantly reduce inflammation, and increase the fibroblast activity [13]. Therefore,
      SynDermix AG created the innovative high-technology, portable medical device SDX-3101
      targeting a disease with high unmet medical need. The device offers a drug-free or eventually
      an add on treatment complying with the maximum demands of safety for the patients potentially
      avoiding undesirable drug effects or surgery. SDX-3101 is indicated for treatment of CRSsNP
      in adults
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SNOT-20 GAV</measure>
    <time_frame>12 weeks</time_frame>
    <description>The primary endpoint is the change in subjective symptoms as quantified by the German validated disease-specific 20-item Sino-nasal Outcome Test (SNOT-20 GAV) after 12 weeks. Superiority is defined as more than minimal clinically important difference (MCID) of 8.9 points to active control of SNOT-20 score at 12 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lund-Kennedy Score</measure>
    <time_frame>day 0, day 14, week 6, 12 and at 6, 9 and 12 months</time_frame>
    <description>We use the Lund-Kennedy endoscopic scoring system to measure the patient's nasal cavity based on there were edema, vesicles, adhesions, scars and polyps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall disease control</measure>
    <time_frame>day 14, week 6, 12 and at 6, 9 and 12 months</time_frame>
    <description>Need for systemic medication, steroid or antibiotic, number of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for surgical intervention</measure>
    <time_frame>day 14, week 6, 12 and at 6, 9 and 12 months</time_frame>
    <description>Capture surgical intervention</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ability to perform normal activities</measure>
    <time_frame>day 0, day 14, week 6, 12 and at 6, 9 and 12 months,</time_frame>
    <description>Measured with the SNOT-20 GAV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of treatment</measure>
    <time_frame>day 14, week 6, 12 and at 6, 9 and 12 months</time_frame>
    <description>Measurement of Visual Analogue Scale 0 to 5, 0 is unacceptable to 5 fully accepted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall score SNOT-20</measure>
    <time_frame>day 0, day 14, week 6, 12 and at 6, 9 and 12 months</time_frame>
    <description>The SNOT-20 has a maximum score of 100 and a minimum score of 0. Higher values represent a worse outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain in the face</measure>
    <time_frame>day 0, day 14, week 6, 12 and at 6, 9 and 12 months</time_frame>
    <description>Measured on a 4-point scale, (0=no symptoms; 1=mild symptoms present, but not troublesome; 2=moderate symptoms that were frequently troublesome but not sufficiently so to interfere with normal daily activities or sleep; 3=severe symptoms that interfered with normal daily activities or sleep)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global impression by investigator</measure>
    <time_frame>day 0, week 6, 12 and at 12 months,</time_frame>
    <description>Measured with Visual Analogue Scale 0 to 10, 0 is unsatisfactory 10 is optimal outcome</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Saccharine test</measure>
    <time_frame>day 0, week 6, 12 weeks and at 12 months</time_frame>
    <description>Evaluate muco-ciliary clearance time</description>
  </other_outcome>
  <other_outcome>
    <measure>Reduction in inflammatory markers</measure>
    <time_frame>day 0, day 14, week 6, 12</time_frame>
    <description>Assessed by Biomarkers: IL-1β, IL-2, IL-4, IL-10, IL-12 and IgE in nasal secretion</description>
  </other_outcome>
  <other_outcome>
    <measure>Exhaled nasal Nitric Oxide (nNO) levels</measure>
    <time_frame>day 0, day 14, week 6, 12 and 12 months</time_frame>
    <description>only in a subpopulation in selected site/s</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Chronic Rhinosinusitis Without Nasal Polyps</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The applied therapeutic vibrations generated by an acoustic coil have a defined sweeping frequency range.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A control device with a different vibration pattern will be used as comparator intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vibration Therapy</intervention_name>
    <description>SDX-3101 is used for drug-free treatment of CRSsNP in adults.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male or female subjects between 18 and 70 years old

          -  Diagnosed history of chronic rhinosinusitis without nasal polyps (CRSsNP) defined as
             per EPOS Guidelines.

          -  Moderate to severe baseline SNOT-20 GAV score (&gt; 20)

          -  Willingness to stop nasal saline irrigation and drug therapy for CRSsNP (restart later
             on possible)

        Exclusion Criteria:

          -  Subjects with local pathology that would compromise the ability to either administer
             the device or assess the benefits/risks (e.g. mucocele, antrochoanal polyp, facial
             trauma, radiation injury, or birth defect)

          -  Systemic corticosteroids if not stop for 14 days before study enrolment

          -  Subjects suffering from insufficiently controlled asthma

          -  Subjects suffering from insufficiently controlled allergic rhinitis (AR)

          -  Subjects with prior sinus operations within the last 4 months

          -  Subjects with known primary ciliary dyskinesia/cystic fibrosis

          -  Subjects with serious underlying medical condition

          -  Ongoing oncological treatments

          -  Known hypersensitivity to materials in direct contact with the skin

          -  Metal or metal-like implant (incl. ceramic) located in the head or neck area.
             Unremovable hearing aids

          -  Patients with implanted cardiac pace-maker

          -  Women who are pregnant or breast feeding

          -  Known or suspected non-compliance, drug or alcohol abuse,

          -  Inability to follow the procedures of the study, e.g. due to language problems,
             psychological disorders, dementia, etc. of the participant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos R Camozzi, MD</last_name>
    <role>Study Director</role>
    <affiliation>SynDermix AG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carlos R Camozzi, MD</last_name>
    <phone>+41 44 503 70 55</phone>
    <email>camozzi@syndermix.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michel M Weber, PhD</last_name>
    <phone>+41 32 513 67 80</phone>
    <email>michel.weber@iss-ag.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kardinal Schwarzenberg Klinikum GmbH</name>
      <address>
        <city>Schwarzach im Pongau</city>
        <zip>5620</zip>
        <country>Austria</country>
      </address>
    </facility>
    <contact>
      <last_name>Florian Kral, Dr. med.</last_name>
      <phone>+43 6415 7101 6220</phone>
      <email>florian.kral@ks-klinikum.at</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Praxis Dr.med. Decot</name>
      <address>
        <city>Dreieich</city>
        <zip>63303</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Elke Decot, Dr. med.</last_name>
      <phone>+ 49 6103 588750</phone>
      <email>info@hnopraxis-decot.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ENT Research Institut für Klinische Studien</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Bergmann Christoph, PD Dr. med.</last_name>
      <phone>+49 201 80 66 640</phone>
      <email>Bergmann@hno-praxis-ruhr.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HNO Praxis am Neckar</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Horn Andreas, Dr. med.</last_name>
      <phone>+49 6221401010</phone>
      <email>HornS04@t-online.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HNO - Arzt Allergologe Studienzentrum</name>
      <address>
        <city>Viernheim</city>
        <zip>68519</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Schindlbeck Gerhard, Dr. med.</last_name>
      <phone>+49 6204 7049888</phone>
      <email>hnoschindlbeck@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Universitätsklinikum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <contact>
      <last_name>Sommer J Ulrich, Dr. med.</last_name>
      <phone>+49 202 896-2276</phone>
      <email>Ulrich.Sommer@helios-gesundheit.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Hals-, Nasen- und Ohrenkrankheiten, Kopf- und Halschirurgie, Inselspital,</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Lukas Anschütz, Dr. med.</last_name>
      <phone>+41 31 632 29 41</phone>
      <email>lukas.anschuetz@insel.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of ENT, Head and Neck Surgery Universitätsspital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Michael Soyka, PD Dr. med</last_name>
      <phone>+41 44 255 58 50</phone>
      <email>michael.soyka@usz.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 5, 2019</study_first_submitted>
  <study_first_submitted_qc>November 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sinusitis</mesh_term>
    <mesh_term>Nasal Polyps</mesh_term>
    <mesh_term>Polyps</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

